Every story as it publishes, newest first.
Nebius just unveiled an asset-light pivot designed to outmaneuver CoreWeave and the miner-to-AI crowd, yet the stock is cratering anyway. Here is what the selloff reveals about which neocloud models can actually survive the…
Live Updates Stay On This Site to Receive Live $ISRG Q2 Earnings Updates3:26pm ETThis live blog is being updated by Thomas Richmond, a 24/7 Wall St. contributor. You’ll get expert analysis of Intuitive Surgical’s…
Live Updates Stay On This Site to Receive Live Netflix Q2 Earnings Updates3:24pm ETThis live blog is being updated by Thomas Richmond, a 24/7 Wall St. contributor. You’ll get expert analysis of Netflix’s Q2…
More than 80% of the AI infrastructure buildout projected through 2028 has yet to happen, and three ETFs are quietly positioning investors to capture what comes next.
Every time Amazon dips, one investor keeps adding shares while Wall Street fixates on a capex blowout that obscures something far more important hiding in the filing.
Social Security's trust funds are burning through reserves faster than most retirees realize, and the window for Congress to act without forcing painful cuts is closing. Here is what the latest Trustees report reveals…
That first Social Security check is supposed to feel like a reward, so discovering it falls short of what you planned for can throw your retirement budget into chaos. A few surprisingly common factors…
IREN stock has shed 41% in a single month alongside every major miner-turned-AI-infrastructure name, but a $3.4 billion NVIDIA contract and zero idle GPUs tell a very different story than the price action suggests.
A common story with an uncommon answer. Picture a woman who just turned 70. She still works an hourly job, rents a small apartment, has about $70,000 in savings, and just started Social Security…
Bank of America just flagged a hidden revenue engine inside Nvidia that the market is still ignoring, and the numbers suggest Wall Street has been pricing the wrong business this entire time.
BNY Mellon and State Street both posted record quarters, but their strategies are moving in opposite directions and only one of them faces a fee war that could quietly erode everything investors are celebrating…
Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment…
Few things ruin a Saturday morning faster than the words “your timing chain is going.” Car repair bills arrive unannounced, cost more than expected, and have a way of landing the same week as…
Arm shares have shed nearly a third of their value since mid-June, and investors now face a fork in the road between a bargain and a value trap. Our proprietary model points firmly in…
Coca-Cola shares are up 22% this year and the stock keeps setting new highs, yet Wall Street's consensus target barely budges. A closer look at the Q1 numbers and two-year earnings trajectory reveals why…
